GlassScriptPhysician profile
Robin R Black
NPI 1962512483
$2,433.08
in general payments reported to CMS, 2019-2025
28 companies · $58.43 in 2025
The $58.43 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $980 · 2022: $701 · 2023: $627 · 2024: $66.96 · 2025: $58.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $726.14 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $244.05 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $144.31 | 2021-2024 | Farxiga |
| Lilly USA, LLC | $140.01 | 2021-2022 | |
| Mylan Specialty L.P. | $129.59 | 2021-2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $128.92 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $117.58 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $92.06 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.85 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $75.03 | 2021-2023 | Austedo |
| Janssen Pharmaceuticals, INC | $72.39 | 2021-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $52.97 | 2022-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $48.42 | 2021 | |
| Medtronic, INC. | $48.31 | 2021-2023 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.91 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $37.44 | 2021-2024 | |
| Axsome Therapeutics, INC. | $34.92 | 2024 | Auvelity |
| Merck Sharp & Dohme LLC | $31.60 | 2021 | |
| Alexion Pharmaceuticals, INC. | $26.65 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.02 | 2022 | |
| Abbott Laboratories | $23.44 | 2022 | |
| Astellas Pharma US INC | $20.54 | 2025 | Veozah |
| Cmp Pharma, INC. | $20.31 | 2021 | |
| Exact Sciences Corporation | $18.43 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $16.29 | 2021 | |
| Lundbeck LLC | $16.01 | 2023 | Rexulti |
| Neurelis, INC. | $15.09 | 2023 | Valtoco |
| Sumitomo Pharma America, INC. | $2.80 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.